Statement by MassBio President & CEO Robert K. Coughlin on the Final FY2020 Budget Conference Committee Report

Jul 22, 2019

“We sincerely thank the House and Senate negotiators for carefully considering the real-world impact of the most significant Medicaid drug pricing legislation in the country and protecting patient access and innovation.”

– Robert K. Coughlin, President and CEO of MassBio

See all MassBio News